Comparative Pharmacology
Head-to-head clinical analysis: ALEVE versus INDO LEMMON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE versus INDO LEMMON.
ALEVE vs INDO-LEMMON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes, reducing inflammation, pain, and fever.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
Oral: 25-50 mg 2-3 times daily. Maximum daily dose: 200 mg.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Renal excretion of unchanged drug and metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for approximately 40%.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)